April 2014
Volume 55, Issue 13
ARVO Annual Meeting Abstract  |   April 2014
Emixustat Hydrochloride for the Potential Treatment of Diabetic Retinopathy (DR)
Author Affiliations & Notes
  • Susan Hayes Henry
    Acucela Inc, Bothell, WA
  • Claes Bavik
    Acucela Inc, Bothell, WA
  • Kuo Lee Lieu
    Acucela Inc, Bothell, WA
  • Andriy Pashko
    Acucela Inc, Bothell, WA
  • Christine Diamond
    Acucela Inc, Bothell, WA
  • Kyoko Mitts
    Acucela Inc, Bothell, WA
  • Jennifer C Lau
    Northwestern University, Evanston, IL
  • Robert A Linsenmeier
    Northwestern University, Evanston, IL
  • David J Calkins
    Vanderbilt University Medical Center, Nashville, TN
  • Ryo Kubota
    Acucela Inc, Bothell, WA
  • Footnotes
    Commercial Relationships Susan Henry, Acucela (E), Acucela (P); Claes Bavik, Acucela (E), Acucela (P); Kuo Lee Lieu, Acucela (E); Andriy Pashko, Acucela (E); Christine Diamond, Acucela (E); Kyoko Mitts, Acucela (E); Jennifer Lau, Acucela (C), Acucela (F); Robert Linsenmeier, Acucela (C), Acucela (F); David Calkins, Acucela (C), Acucela (F); Ryo Kubota, Acucela (E), Acucela (P)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 1061. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Susan Hayes Henry, Claes Bavik, Kuo Lee Lieu, Andriy Pashko, Christine Diamond, Kyoko Mitts, Jennifer C Lau, Robert A Linsenmeier, David J Calkins, Ryo Kubota; Emixustat Hydrochloride for the Potential Treatment of Diabetic Retinopathy (DR). Invest. Ophthalmol. Vis. Sci. 2014;55(13):1061.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: Hypoxia caused by ischemia plays a role in DR and is exacerbated during dark adaptation. Preclinical studies were undertaken to investigate the potential for emixustat HCl to reduce dark current and decrease photoreceptor oxygen (O2) consumption toward values observed in light adaptation.

Methods: To test reduction in dark current, the Mn2+-enhanced magnetic resonance imaging (MEMRI) signal was used as a surrogate for retinal cGMP-gated cation channel current. Brown Norway rats (5/group) were given single doses of 1 or 10 mg/kg emixustat or vehicle by oral gavage, then 2 hours later, treated with tropicamide for pupil dilation and photobleached (5000 Lux white light for 10 minutes). Animals were then treated with Mn2+Cl and MEMRI measurements were obtained. To measure retinal PO2, urethane anesthetized Long Evans rats (3/group) were treated (emixustat 1 mg/kg IV) or left untreated, photobleached 30-60 minutes later (1000 Lux white light for 15 minutes), and then electroretinograms (ERGs) and retinal PO2 profiles were recorded with microelectrodes.

Results: When dark current reduction was studied, vehicle-treated rats had increases in cation channel activity after photobleach consistent with those expected by dark adaptation. Emixustat-treated rats showed a dose-dependent reduction in cation channel activity, indicative of a reduction in dark current. This reduction was statistically significant compared to control (P = 0.002). When retinal PO2 was studied, ERGs recovered in the untreated rats but remained fully suppressed in emixustat-treated rats during the 2.5 hours after photobleaching, indicating a delay in dark adaptation. PO2 in the photoreceptor layers decreased toward the level observed in dark adaptation after photobleach, but remained elevated in emixustat-treated rats, consistent with the hypothesis that emixustat would delay dark adaptation and thereby reduce associated high photoreceptor oxygen consumption.

Conclusions: Reduction of the dark current, as observed in emixustat-treated rats would be expected to reduce the metabolic activity of the photoreceptors in the outer retina. This reduction in metabolic activity was demonstrated independently by a prolonged elevation in retinal PO2 which, in turn, may prevent hypoxia in the retina and delay the progression of diabetic retinopathy.

Keywords: 499 diabetic retinopathy • 548 hypoxia • 648 photoreceptors  

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.